CD274 and non-small cell lung carcinoma: Of note, anti-PD-1 therapy (pembrolizumab) has recently replaced chemotherapy in the first line treatment for NSCLC with high PD-L1 expression, and the addition of pembrolizumab to platinum chemotherapy resulted in a significant improvement in overall survival (OS) in patients with non-squamous NSCLC, regardless of PD-L1 expression.